Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/4gmoGgD
JAMA Cardiology’s Post
More Relevant Posts
-
Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/49rxMqr
-
-
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/3ZIKU61
-
-
A revolutionary new perception on anticoagulation treatment in patients with ACS undergoing PCI with DES. New insights that will most probably impact the upcoming guidelines
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
-
-
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
-
-
Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/4frqg0z
-
-
Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/3A3usEs
-
-
Most viewed in the last 7 days from JAMA Cardiology: Study examines the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with left ventricular ejection fraction of 60% or greater. https://ja.ma/3zOc0Qb
-
-
Most viewed in the last 7 days from JAMA Cardiology: Are ticagrelor or clopidogrel monotherapy after PCI and 1 to 3 month DAPT similarly effective and safer compared with standard DAPT? https://ja.ma/4aCIxWd
-
-
ApoB has been the standard for many years. However, it hasn't even scratched the surface in clinical workflows. I suspect it will be another decade before it will be the standard of care. The reasons for this is that many medical groups are still using pre-printed (paper) for ordering labs, EHR order sets haven't been updated, patients still rely on outdated HDL and TG data, and reimbursement packages don't mention apoB and Lp(a). Lipidology isn't the only field in healthcare affected by entrenchment. This is health literacy. Not a curse word, but a patient empowerment tool.
For those who think when TG is high, TG (instead of apoB) or even LDL-C is the goal of therapy, this review is so important. Time for apoB to be what lipid & ASCVD guidelines are focused on. National Lipid Association European Atherosclerosis Society European Society of Cardiology https://lnkd.in/eJhduBFF
-
-
For those who think when TG is high, TG (instead of apoB) or even LDL-C is the goal of therapy, this review is so important. Time for apoB to be what lipid & ASCVD guidelines are focused on. National Lipid Association European Atherosclerosis Society European Society of Cardiology https://lnkd.in/eJhduBFF
-
